Stevanato Group S.p.A. (STVN)
Data as of Nov 3, 2:04 PM ETPrices may be delayedHow our data works
Res / Sup are automatic swing levels for educational reference only — not signals or advice.
Prices may be delayed. For informational purposes only — not investment advice.
STVN key stats
STVN GlowScore: Quiet
A 0–100 read on today's activity from volume, momentum and intraday range. Not a buy or sell signal.
About Stevanato Group S.p.A.
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
What's moving STVN today
Updated November 3, 2026As of November 3, 2026, Stevanato Group S.p.A. (STVN) stock tumbled to $14.56, down 26.24% (-$5.18) versus the previous close. On the day, shares have traded between $13.03 and $15.58. That puts STVN in the lower third of its 52-week range of $12.89 to $27.00. Stevanato Group S.p.A. carries a market capitalization of roughly $5.39 billion, with about 3.27 million shares changing hands.
Latest STVN news
- Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue EstimatesYahoo Finance· Nov 3, 7:00 AM ET
- Stevanato: Q3 Earnings SnapshotYahoo Finance· Nov 3, 6:49 AM ETAP
- Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026Yahoo Finance· Nov 3, 6:30 AM ET
- Stevanato Group S.p.A. (STVN) Rallies on 2Q26 Revenue Growth and EBITDA Margin ExpansionYahoo Finance· Oct 28, 12:15 PM ET
- Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System SelectionYahoo Finance· Oct 27, 7:00 AM ET
- Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System SelectionYahoo Finance· Oct 27, 7:00 AM ET
- Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026Yahoo Finance· Oct 20, 4:30 PM ETEDT
- Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American InjectablesYahoo Finance· Oct 1, 9:00 AM ET
Source: Yahoo Finance RSS · Updated November 3, 2026
Want STVN headlines, alerts and AI research in one place? Create a free account →
STVN buzz on Stocktwits
195 watchers$STVN Just browsing headlines, everything reads well. Did they lower guidance?
@Roaring_Capybara· Nov 3, 1:22 PM ET
$STVN took some of that glp1 and slimmed down
@Lowkeyoptions· Nov 3, 1:12 PM ET
$STVN The score risen to close to 80%
@TrvdeApp· Nov 3, 12:59 PM ET
$STVN In at 14.5. Overreaction
@kikmontero· Nov 3, 10:04 AM ET· Bullish
https://www.marketbeat.com/earnings/reports/2026-11-3-stevanato-group-spa-stock/ $STVN Stevanato Group Earnings Transcript
@EarningsInsider· Nov 3, 10:03 AM ET
Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →
STVN Congress & insider trades
Congress amounts are the disclosed ranges; filings can lag the trade date by up to 45 days.
AI research on STVN
Get an instant AI breakdown of the bull & bear case, key risks, and what analysts are watching.
Not financial advice. This page is for educational purposes only. Data comes from third-party sources, may be delayed or incomplete, and should not be the basis of any investment decision.